Form 4: Xilio Therapeutics Reprices Executive Stock Options

Xilio Therapeutics has repriced certain stock options for SVP Kevin Brennan to $1.00 per share and approved a new 2025 Stock Incentive Plan.

Summary

• Xilio Therapeutics, Inc. (XLO) has repriced certain stock options held by Kevin M. Brennan, SVP, Finance and Accounting, effective November 21, 2025.
• The repricing reduced the exercise price of specific stock options to $1.00 per share, unless exercised before November 21, 2026, in which case the original exercise price applies.
• A new stock option for 131,700 shares was granted to Mr. Brennan on October 8, 2025, with an exercise price of $0.841, subject to stockholder approval of the 2025 Stock Incentive Plan.
• Stockholders approved the adoption of the 2025 Stock Incentive Plan on November 21, 2025.
• The 131,700 new options will vest in 36 equal monthly installments starting December 21, 2025, contingent on continued service.
• Options for 55,000 shares (granted April 1, 2023) with an original exercise price of $3.17 were repriced to $1.00; 25% vested March 30, 2024, with the remaining 75% vesting monthly through March 30, 2027.
• Options for 25,000 shares (granted prior to August 15, 2033 expiration) with an original exercise price of $2.785 were repriced to $1.00.
• Options for 20,000 shares (granted May 1, 2024) with an original exercise price of $1.08 were repriced to $1.00; these options began vesting June 1, 2024, and continue monthly through May 1, 2028.
• Following these transactions, Mr. Brennan beneficially owns 231,700 derivative securities (stock options).

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the new incentive plan and repricing aim to re-motivate management, the necessity of repricing indicates significant past stock underperformance. This is a negative signal for existing shareholders, though the re-incentivization could be seen as a positive for future operational focus.

Positives

• The adoption of the 2025 Stock Incentive Plan provides a framework for future equity-based compensation, aligning management incentives with long-term company performance.
• The option repricing re-incentivizes SVP Kevin Brennan by making previously 'underwater' options more valuable, potentially boosting motivation and retention.

Negatives

• The repricing of stock options typically indicates a significant decline in the company's stock price, suggesting past underperformance.
• Repricing existing options can be viewed negatively by shareholders as it effectively grants new value to executives without requiring a corresponding increase in stock price from the original grant date.

Risks

• Shareholder dilution risk from the issuance of new options and the potential exercise of repriced options at a lower cost.
• Perception risk that the repricing signals a lack of confidence in the company's ability to achieve higher stock prices without such adjustments.
• Potential for reduced shareholder value if the repriced options are exercised and sold, increasing the float at a lower effective cost to the insider.

Future Outlook

The adoption of the 2025 Stock Incentive Plan and the repricing of existing options are forward-looking actions designed to re-incentivize management and align their interests with future stock price appreciation, suggesting a strategic focus on future performance and value creation.

Management Comments

• The Board of Directors approved the adoption of the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan, subject to stockholder approval.
• The Compensation Committee of the Board granted 'Tranche 1 Options' to the Reporting Person, subject to stockholder approval of the 2025 Plan.
• The option repricing reduced the exercise price of each repriced option to $1.00 per share unless such repriced stock option is exercised prior to November 21, 2026, in which case the original exercise price must be paid.

Industry Context

Stock option repricing is a common practice in the biotechnology and pharmaceutical industries, particularly for early-stage companies or those experiencing significant stock price volatility. It is often employed to retain and motivate key executives when original option grants become 'underwater' due to market downturns or company-specific challenges, ensuring that incentives remain effective for future performance.

Comparison to Industry Standards

• Option repricing is a recognized, albeit sometimes controversial, tool used by companies, especially in high-risk, high-reward sectors like biotech, to re-align executive incentives when stock performance lags. Companies such as Biogen (BIIB) or Moderna (MRNA) have, at various points, faced similar challenges in managing executive compensation amidst stock volatility, though specific repricing events vary.
• The adoption of a new stock incentive plan, like Xilio's 2025 Plan, is standard practice for public companies to ensure a continuous pool of equity awards for attracting and retaining talent, comparable to plans seen at peers like Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY).
• The vesting schedules (e.g., 36 equal monthly installments over three years) are typical for executive stock options, designed to promote long-term retention and performance, consistent with practices observed across the broader biotech industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from new and repriced options; re-incentivized management may lead to improved future performance, but the repricing itself reflects past underperformance.
• Employees (specifically Kevin M. Brennan): Re-incentivized with more 'in-the-money' options, potentially increasing motivation and retention.

Next Steps

• Continued vesting of the 131,700 'Tranche 1 Options' in 36 equal monthly installments beginning December 21, 2025.
• Continued vesting of the remaining 75% of 55,000 stock options (granted April 1, 2023) in monthly installments through March 30, 2027.
• Continued vesting of 20,000 stock options (granted May 1, 2024) in monthly installments through May 1, 2028.
• Potential exercise of repriced options by Kevin M. Brennan, with the exercise price dependent on the date of exercise relative to November 21, 2026.

Key Dates

Recommendation

This Form 4 filing details insider transactions and a significant repricing event, which typically follows a substantial decline in stock price. While the repricing and new incentive plan aim to re-motivate management, the underlying reason for repricing (poor past stock performance) is a concern. Without a broader financial context or strategic update, a definitive 'buy' or 'sell' recommendation is premature. Investors should 'hold' and monitor future financial reports and strategic developments to assess the effectiveness of these incentives and the company's overall trajectory.

Keywords

Xilio Therapeutics, XLO, Stock Options, Option Repricing, SEC Form 4, Insider Transaction, Executive Compensation, Stock Incentive Plan, Corporate Governance, Biotechnology